January 27, 2017 06:31 AM ESTUpdated January 30, 03:27 PM
News Briefing

No­var­tis silent­ly yanks a trou­bled biosim­i­lar ap­pli­ca­tion; Chi­nese an­ti­body de­vel­op­er draws $39M round

Shehla Shakoor

Managing Director

• No­var­tis nev­er has tried to ex­plain why the FDA has re­ject­ed its biosim­i­lar of Am­gen’s Neu­las­ta. And it’s be­ing equal­ly ret­i­cent about its de­ci­sion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times